Deep, targeted next-generation sequencing has unveiled that subclonal mutations (i.e., All those present in just a portion of tumor cells) is often detected for all driver genes and they are related to fast disorder development and poor outcome.11–13 This is especially applicable for TP53mutations, missing their unfavorable influence in patients